Should we look for silent pulmonary embolism in patients with deep venous thrombosis? by unknown
García-Fuster et al. BMC Cardiovascular Disorders 2014, 14:178
http://www.biomedcentral.com/1471-2261/14/178RESEARCH ARTICLE Open AccessShould we look for silent pulmonary embolism in
patients with deep venous thrombosis?
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Maria José Forner1,2 and Fernando Martínez1,2,3Abstract
Background: Asymptomatic or silent pulmonary embolism (S-PE) in patients with deep vein thrombosis has been
the focus of numerous publications with the objective of determining the incidence of S-PE and assessing whether
its existence has any clinical or therapeutic consequences that outweigh the risks associated with the diagnostic
tests performed and the increased healthcare costs. The objectives were to assess the incidence of S-PE using
computed tomography angiogram (CTA), to understand the epidemiological factors that might trigger embolism,
and to assess whether D-dimer (DD) predicts the existence of S-PE’s.
Methods: A prospective and consecutive assessment of 103 hospitalized patients with lower limb DVT in the
absence of PE symptoms, using CT scan. DD was quantified before anticoagulation. The risk factors and
characteristics of the DVT were studied. A three-year follow-up assessing risk recurrence and clinical outcome was
performed.
Results: The incidence of S-PE was 66%. In 77% of these cases, the main and lobar pulmonary arteries were
affected. Iliac and femoral DVTs most often produced S-PE. ROC curve with a DD value higher than 578 ng/ml
provided good sensitivity but low specificity to identify patients with S-PE. Diagnosis entailed higher hospitalization
expenses. No significant recurrence rate of thrombotic events was observed in the S-PE group during the follow-up.
Conclusions: The incidence of S-PE in lower-limb DVT is high, but in the absence of symptoms, diagnosis does not
appear to be necessary, as there are no short- or long-term clinical or therapeutic consequences.
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Asymptomatic or silent pulmonary embolism (S-PE) in
patients with deep vein thrombosis was first described
by Kistner [1]. Subsequently, it has been the focus of
numerous publications with the objective of determining
the incidence of S-PE and assessing whether its exist-
ence has any clinical or therapeutic consequences that
outweigh the risks associated with the diagnostic tests
performed and the increased healthcare costs [2-15].
To date the results have been very disparate. Findings
show an incidence ranging between 11% and 59% [3-8].
All published studies have been retrospective, and most
have used ventilation-perfusion (V/Q) scintigraphy as* Correspondence: garciafuster_mjo@gva.es
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unless otherwise stated.the method of diagnosis. Stein et al. [7], in a meta-
analysis from 2010, which included 28 publications,
found an average incidence of S-PE of 32%. Most pub-
lished studies have found no advantage associated with
diagnosis [10,11] but the RIETE [8] group, however, re-
cently observed that patients with deep venous thrombosis
and S-PE had an increased recurrence of symptomatic PE
during the first 15 days after thrombosis. This might
suggest the need for stricter surveillance during this time
period or perhaps the need for a vena cava filter.
The objectives of the present study were to prospect-
ively estimate the incidence of S-PE in a group of
patients with lower limb DVT, to assess the risk factors
and characteristics of DVT that may have influenced
their origin, and to assess the economic and clinical
impact of diagnosis in both the short and long term.entral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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This was a prospective study of 103 patients, who were
admitted consecutively to the Department of Internal
Medicine, University Hospital Clinico of Valencia in 2009
for lower limb DVT without symptoms suggestive of
pulmonary embolism (dyspnea, chest pain, hypotension,
dizziness, fainting, sweating, tachycardia, low O2 satur-
ation). The study was in compliance with the Helsinki
Declaration and was approved by the Ethical Committee
of the Hospital. Informed written consent was obtained
from all participants.
The thrombosis were diagnosed by duplex Doppler
ultrasound probe (Siemens Antares VF10-5), using the
following criteria: visualization of a hypoechoic structure
within the vein, passive distension of the vein or absence
of local or distal compressibility and changes in venous
flow dynamics [16,17]. All patients underwent angio-
pulmonary CT with a multidetector CT 16 and subse-
quent evaluation of the images in axial cuts and coronal
reconstructions. The positive criterion was a filling
defect, in place of the contrast, in a space in a lung
artery. The extent of the contrast defect could be total or
partial and, in the latter case, either as a ring or at an angle
to the vessel wall [18]. Anthropometric data were
collected: a) history of arterial risk factors (hypertension,
diabetes, dyslipidemia) and b) venous risk factors
(immobilization, surgery in the previous two months,
hormone therapy). The morphological features of
localization and extension of the thromboses and lung
embolisms were assessed. The D-dimer was quantified
before starting anticoagulation using D-dimer plus/BCS
(quantitative turbidimetric assay) (Dade Behring Marburg
GmbH). Normal values were considered to be <250 ng/ml.
All patients were treated according to protocol,
which consisted of 3-5 days of low molecular weight
heparin, adjusted for weight, followed by orally admin-
istered antagonists of vitamin K drugs (Acenocumarol)
until an INR ≥2 was achieved, at that point, the heparin
was removed. Patients received Acenocumarol for at least
6 months. The cost of care, along with the length of
hospital stay, was calculated for patients with and without
S-PE.
Patients were followed for three years and were
assessed for hospital readmissions from causes of
thromboembolic disease, other diseases and the pres-
ence of clinical data that might indicate the presence
of pulmonary hypertension.
We calculated the means and standard deviations for
absolute values. Continuous variables were compared
with Student's t test, and categorical variables with chi-
square or Fisher's exact test if necessary. The predict-
ive power of DD as a suspected diagnosis using ROC
curves and the area under the curve, and the Youden
index was calculated.Results
General characteristics of the study population
A total of 103 patients, 59 men and 44 women, were
included. The age ranged between 17 and 90 years with a
mean of 61.5 (SD 19). There were 46 hypertensives, 18
diabetics and 30 dyslipidemics. In 22 subjects, risk factors
for venous risk found were trauma, surgery and hormone
treatment. The thrombosis was ilio-femoral in 92 patients
and distal, popliteal or more, in 11. It affected the right leg
in 46 patients, the left in 57, and was bilateral in 5.
Silent pulmonary embolism
From the 103 patients included in the study, S-PE was
observed in 68, a prevalence of 66%. Age, sex, risk factors,
and the venous thrombosis characteristics in triggering S-
PE is reflected in Table 1, which shows that none of the
analyzed factors had a greater presence in S-PE patients as
compared to those without S-PE. The main pulmonary
artery was affected in 35% of the cases, lobar arteries in
42% of the cases, and segmental ones in 23%.
Predictive value of D-dimer
The predictive value of the DD values was analyzed for
the presence of S-PE in 94 subjects by ROC curves.
Values >578 ng/ml were discriminant (area under the
curve of 0.64 and p = 0.025) with a sensitivity of 80%
and a specificity of 43% (Figure 1). The positive predict-
ive value for this point was 76.5%, and the negative pre-
dictive value was 50%. Dividing the sample into three
groups according to the DD values, ≤250 ng/ml, 251 to
578 ng/ml and >578 ng/ml, it was observed that the pa-
tients with S-PE were more frequently in the group with
the higher DD value (p = 0.04) (Table 2).
Follow-up
The average days of hospitalization were 9.86 (SD 3.8)
for those without S-PE and 10.18 (SD 4.7) for those with
S-PE. There were no clinical episodes suggestive of
pulmonary embolism. During the three years of follow
up, 25 patients were hospitalized for various reasons: 8
of the 35 who had no S-PE (23%) and 17 of the 68 who
had S-PE (25%), with no significant differences. Of all
readmissions, only 3 were for venous thromboembolism
and 2 of these occurred in patients with a history of
S-PE. The incidence of venous thromboembolic events
was 0.96/100 patients/year for the S-PE group and
1.08/100 patient-years for the rest. All readmissions
were for new DVT while none were for PE.
Health care costs
All patients underwent a CT angiogram, which repre-
sented a single cost of 300€ more per patient. In cases in
which S-PE was detected, the stay was prolonged by half
a day, which entailed an additional cost of 275€.
Table 1 General characteristics and deep venous thrombosis risk factors
All S-PE No S-PE OR p
Age (yr) 61.5 (19) 61.2 (19.4) 60.1 (18.8) 1.12 (-6.83-9.07) 0.78
Males 59 (57%) 42 (61.8%) 17 (48.6%) 0.59 (0.26-1.13) 0.22
Risk factors
Venous* 22 (21.4%) 13 (19.1%) 9 (25.7%) 0.68 (0.26-1.80) 0.45
Hypertension 46 (44.7%) 30 (44.1%) 16 (45.7%) 0.94 (0.41-2.13) 1
Type 2 diabetes 18 (17.5%) 13 (19.1%) 5 (14.3%) 1.41 (0.46-4.36) 0.60
Dyslipidemia 30 (29.1%) 19 (27.2%) 11 (31.4%) 0.84 (0.35-2.06) 0.82
DVT location
Ileo-femoral 92 (89.3%) 62 (91.2%) 30 (85.7%) 0.58 (0.17-2.56) 0.50
Poplitea 11 (10.7%) 6 (8.8%) 5 (14.3%)
DVT lateratity
Right leg 46 (44.7%) 28 (41.2%) 18 (51.4%) 1.5 (0.66-3.43) 0.40
Left leg 57 (55.3%) 40 (58.8%) 17 (48.6%)
Bilateral 5 (4.9%) 5 (7.4%) 0 0.64 (0.55-0.74) 0.16
S-PE Silent Pulmonary Embolism; *Venous risk factors (VRF) at least one of the following: immobilization, two months previous surgery, hormone therapy.
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In this study the prevalence of subjects with lower limb
DVT which presented S-PE was 66%. The location of
the thrombus in the iliac and femoral veins was frequent
and the DD valuation had low specificity. The diagnosis
of silent pulmonary embolism does not seem to offerFigure 1 Predictive value of D-dimer for pulmonary embolism. ROC cany short- or long-term benefit and is an additional risk
to the patient because of the administration and in-
creased healthcare costs.
The percentage of silent pulmonary embolisms found
in patients with DVT in this study is much higher
than in previously published studies. Decousus et al.urve (see text).
Table 2 Distribution of D-dimmer value in patients with
and without silent pulmonary embolism
All S-PE (%) No S-PE (%)
DD <250 ng/ml 11 4 (6.3) 7 (23.3)
DD 251-578 ng/ml 14 9 (14.1) 5 (16.7)
DD >578 ng/ml 69 51(79.7) 18 (60)
DD (D-dimer), S-PE (silent pumonary embolism).
Chi-square p value 0.04.
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lence of 11%, most of whom had undergone a ventilation-
perfusion scintigraphy. Monreal et al. [6] reported a 26%
incidence while evaluating 1000 patients, also diagnosed
by V/Q scintigraphy. Meignan et al. [5] evaluated 379 pa-
tients with the same method, and the incidence was 32%.
This figure were similar to that found by Stein [7] in a
meta-analysis in 2010, which noted that the diagnostic
method used in most studies was V/Q scintigraphy, a
method which has an 82% sensitivity for high or inter-
mediate probability according the PIOPED (Prospective
Investigation of Pulmonary Embolism Diagnosis) criteria.
[12,13]. Paul et al. [4] are the only authors found in the
literature with an incidence of 59%, similar to that found
in our study, because they used tomography or pulmonary
angiography as their diagnostic methods.
In patients with S-PE, there appears to be a discrete
higher prevalence in men than in women, a finding not
corroborated with those from previous studies in which the
percentage was the same for both sexes [6]. A higher inci-
dence of S-PE was found in the elderly patients than in the
younger ones, which is similar to that described by other
authors [5,14,15]. This is not surprising given that throm-
botic events increase with age. There was no evidence
found that the cardiovascular risk factors, hypertension,
diabetes mellitus and dyslipidemia, have any influence on
the risk of S-PE. The same can be said for the transient
venous thrombotic risk factors studied. Genetic thrombo-
philia was not included among the venous risk factors be-
cause a systematic study was not performed on all patients,
only on the younger ones. The fact that the embolization of
ilio-femoral thromboses is more frequent than the popliteal
is to be expected, as it also is in symptomatic pulmonary
embolisms [19-22].
Despite having no clinical impact, the main pulmonary
and/or lobar arteries were affected in 77% of the cases.
This is the authors’ main argument for defending the ap-
propriateness of their diagnosis. It is known that the ap-
pearance of subsequent pulmonary vascular complications
after embolisms, such as the development of pulmonary
hypertension, impaired arterial-alveolar 02 gradient, or the
creation of dead spaces [2], depends largely on the affected
vascular bed. The short and long-term monitoring con-
ducted in this study, however, did not observe the appear-
ance of any clinical data to suspect new PE or any other ofthe complications described. Nonetheless, it is possible
that the increment in pulmonary arterial pressure may
exist without any clinical repercussions during the time of
observation.
D-dimer, a degradation byproduct of fibrin, has been
used for years as a marker of thromboembolic events
despite the handicap that results from its low specificity.
Likewise, the different detection methods used to com-
bine findings (ELISA or turbidimetric) hinder forming
conclusions23. In principle, non-elevation is of great
interest as an indicator to exclude the existence of
pulmonary embolisms. The accepted significant figure of
several authors is around 500 ng/ml, to consider their
existence [13,23-25]. The present study found that a
value of 578 ng/ml was discriminative of the presence of
PE but with a low sensitivity and even low specificity.
80% and 43%, respectively.
The hospital stay for patients with S-PE extends by an
additional half day, suggesting that their existence does not
complicate the illness. Hospital costs per patient, however,
increase as a result of the cost of the CT angiography and
the longer stay. While this this does not represent an im-
portant figure per patient, in itself, it can become one when
considering the total number of patients who undergo CT
angiography. The risk to the patient from the use of con-
trast and the unnecessary irradiation is an argument to
consider, especially since it is usually performed in elderly
patients whose renal function is frequently compromised
[26,27]. In these conditions, the potential risk could be
avoided by using a combined perfusion scintigraphy with
chest radiography as recommended by Sostman [28].
There are two arguments in defense of the investigation
of a silent pulmonary embolism in patients with deep vein
thrombosis. The first is that those who have suffered a pul-
monary embolism are at increased risk of embolic recur-
rence, especially in the first 15 days [8]. The second is the
concern that if PE is found during follow-up, it may be
incorrectly diagnosed as a new PE resulting from a failure
of anticoagulants. According to the ACCP guidelines [29],
these would be situations which required the placement of
a vena cava filter. That notwithstanding, the present study
did not identify an increment in embolic events in the short
or long term. In the three-year follow-up, the incidence of
thromboembolic events was 2.8% for the same two groups
of patients, lower than the previously reported by other au-
thors for thrombosis [30]. What the present study did find
was a greater number of readmissions for other diseases in
the group of patients with S-PE, which could be interpreted
as a higher comorbidity, since there were no differences in
the risk of recurrence of thromboembolic disease.
The results of the present study should be considered
within its strengths and limitations. A prospective design
and 3 year follow-up give credit to the results. On the
other hand the sample size is relatively small.
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This study found an incidence of silent pulmonary
embolism of 66% for lower limb DVT, much higher than
that reported previously. These are more frequent when
the proximal veins were affected. The figure of DD has a
low specificity in the diagnosis. According to this study
the confirmation of S-PE appears unnecessary since its
presence does not imply an increase in immediate or
delayed morbidity or a change in treatment strategy.
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